SciSparc vs XTL Biopharmaceuticals
SPRC and XTLB side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How SPRC and XTLB compare
SciSparc scores higher on the StockData Score (3 against 0 for XTL Biopharmaceuticals), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | SPRC | XTLB |
|---|---|---|
| Size and price | ||
| Share price | $0.398 | $1.66 |
| Change, 1 year | −98.4% | −56.0% |
| Change, 5 years | −100.0% | −87.5% |
| Beta (5Y) | 0.33 | 0.99 |
| Employees | 3 | 3 |
| StockData Score | ||
| Total score | 3 (better) | 0 |
| Valuation score | 0 | 0 |
| Growth score | 1 (better) | 0 |
| Performance score | 0 | 0 |
| Health score | 2 (better) | 0 |
| Dividend score | 0 | 0 |
| Growth | ||
| Revenue growth (TTM) | −34.5% | – |
| EPS growth (TTM) | −51.9% | – |
| EPS growth, 5Y average | 36.4% | – |
| Profitability | ||
| Gross margin | 73.7% | – |
| Operating margin | −978% | – |
| Net margin | −1423% | – |
| Return on equity | −770% | – |
| Financial health | ||
| Debt / equity | 0.09 | – |
| Interest coverage | −1.0× (better) | −6.3× |
| Current ratio | 0.87 | – |
| Piotroski F-score | 3 | – |
| Ownership | ||
| Held by institutions | – | 0.00% |
| Held by insiders | 15.6% | 0.00% |
| Insider net buying, 12 months | −$4.6K | – |
| Short interest, % of float | 22.5% | – |
Go deeper
- SPRC stock overview
- SPRC income statement
- SPRC valuation and score
- XTLB stock overview
- XTLB income statement
- XTLB valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.